Research Article

Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer

Table 4

Comparison of miR-155 expression among clinical categories.

Pathological categoriesSample size-fold (vs. control) (ANOVAǂ) (vs. control) (Tukey)

Normal36
Histology grade
 WD10<0.0010.016
 MD15<0.001
 PD11<0.001

TNM stage
 Stage I8<0.0010.002
 Stage II17<0.001
 Stage III11<0.001

Tumor size ()
 T1 ()11<0.0010.0015
 T2 ()18<0.001
 T3 ()7<0.001

Lymph node involvement ()
 Yes170.15<0.001
 No19<0.001

Estrogen receptor (ER)
 ER+240.84<0.001
 ER-12<0.001

Progesterone receptor (PR)
 PR+190.54<0.001
 PR-17<0.001

HER2
 HER+90.79<0.001
 HER-27<0.001

Ki-67
 ≤10%140.9<0.001
 >10%22<0.001

WD = grade 1; MD = grade 2; PD = grade 3; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2. ǂThe analysis of variance (ANOVA) was performed for the analysis. Tukey multiple comparison.